조현병 신규 치료법(2026년 2분기)

The Global Schizophrenia Emerging Therapies Market is estimated to grow from USD 3.94 billion in 2026 at a CAGR of 26.7% to USD 33.11 billion in 2031.

The global schizophrenia emerging therapies market is undergoing significant transformation as advances in neuroscience, molecular biology, precision medicine, and digital health accelerate the development of innovative treatment approaches. Emerging therapies analysis provides comprehensive insights into investigational drugs, novel mechanisms of action, clinical development pipelines, regulatory progress, licensing activities, strategic collaborations, and commercialization opportunities. As schizophrenia continues to impose a substantial clinical and socioeconomic burden worldwide, pharmaceutical companies and biotechnology firms are intensifying research efforts to develop therapies that address both positive and negative symptoms, improve cognitive function, and reduce relapse rates.

Schizophrenia is a chronic and severe psychiatric disorder characterized by hallucinations, delusions, disorganized thinking, cognitive impairment, and emotional dysfunction. Conventional antipsychotic medications have significantly improved disease management; however, many patients continue to experience residual symptoms, treatment resistance, medication-related adverse effects, and poor long-term adherence. These unmet clinical needs have accelerated the development of next-generation therapies designed to provide improved efficacy, enhanced safety, and better functional outcomes.

The emerging therapeutic landscape is becoming increasingly diverse, encompassing novel antipsychotics, glutamatergic modulators, muscarinic receptor agonists, dopamine receptor modulators, anti-inflammatory therapies, neuroprotective agents, gene-based approaches, digital therapeutics, and long-acting injectable formulations. Researchers are also investigating therapies targeting cognitive impairment and negative symptoms, areas where currently approved treatments offer limited clinical benefit. Advances in biomarker research and precision psychiatry are supporting more personalized treatment strategies and improving patient selection for clinical trials.

Technological innovations, including artificial intelligence-assisted drug discovery, digital biomarkers, wearable monitoring devices, and decentralized clinical trials, are improving research efficiency and accelerating therapeutic development. Strategic partnerships among pharmaceutical companies, biotechnology firms, academic institutions, and contract research organizations continue to strengthen the innovation ecosystem, while supportive regulatory initiatives for mental health disorders encourage continued investment in novel therapeutic development.

Market Drivers

Rising Global Burden of Schizophrenia

The increasing prevalence of schizophrenia and its long-term impact on healthcare systems continue to drive demand for innovative treatment options.

Growing recognition of unmet medical needs is encouraging investment in advanced therapeutic research.

Increasing Investment in Neuroscience Research

Pharmaceutical companies, biotechnology firms, and research organizations continue expanding investment in psychiatric drug development.

Increased funding is supporting the discovery of therapies with novel mechanisms of action and improved safety profiles.

Advancements in Precision Psychiatry

Progress in genetics, biomarker discovery, and neuroimaging is enabling more personalized approaches to schizophrenia treatment.

Precision medicine is expected to improve patient selection, treatment response, and long-term clinical outcomes.

Development of Novel Mechanisms of Action

Researchers are expanding beyond traditional dopamine-targeted therapies to investigate glutamatergic pathways, muscarinic receptors, inflammatory mechanisms, and synaptic function.

These innovative approaches aim to address symptoms that remain inadequately managed by existing therapies.

Growth of Long-Acting and Digital Therapeutics

Long-acting injectable antipsychotics, digital therapeutics, remote patient monitoring, and mobile health technologies are improving treatment adherence and disease management.

These technologies support continuous patient monitoring and facilitate more personalized care.

Market Restraints

High Clinical Development Risk

Psychiatric drug development is associated with lengthy clinical trials, complex efficacy assessments, and high rates of late-stage clinical failure.

These challenges increase development costs and commercialization risk.

Complex Disease Biology

The multifactorial nature of schizophrenia complicates therapeutic development and limits the effectiveness of single-target treatment strategies.

Heterogeneous patient populations require increasingly personalized approaches.

Regulatory and Reimbursement Challenges

Novel psychiatric therapies often require extensive clinical evidence demonstrating long-term efficacy, safety, and cost-effectiveness before achieving regulatory approval and reimbursement.

Market access may therefore require prolonged evaluation.

Technology and Segment Insights

By Therapy Type

Novel antipsychotics continue to represent the largest segment of the emerging pipeline, focusing on improved efficacy and reduced adverse effects.

Additional therapeutic categories include muscarinic receptor agonists, glutamatergic modulators, dopamine receptor stabilizers, anti-inflammatory agents, neuroprotective therapies, cognitive enhancers, gene-based treatments, and digital therapeutics.

By Development Stage

Preclinical and Phase I candidates account for a significant portion of the innovation pipeline as researchers investigate new molecular targets.

Phase II and Phase III programs are expanding as promising therapies demonstrate encouraging safety, tolerability, and efficacy in clinical studies.

By Route of Administration

Oral therapies remain the dominant treatment approach due to convenience and widespread patient acceptance.

Long-acting injectable formulations continue gaining importance by improving medication adherence and reducing relapse frequency, while emerging delivery technologies may further diversify treatment options.

By End User

Hospitals, psychiatric care centers, and specialty mental health clinics remain the primary settings for schizophrenia treatment.

Academic medical centers and clinical research organizations continue supporting therapeutic development through multicenter clinical trials and translational research.

Regional Insights

North America dominates the global schizophrenia emerging therapies market owing to advanced pharmaceutical research, strong investment in neuroscience, established regulatory pathways, and extensive clinical trial infrastructure. The United States remains the leading center for psychiatric drug innovation and commercialization.

Europe represents another major market supported by collaborative mental health research programs, strong academic institutions, comprehensive healthcare systems, and increasing adoption of precision psychiatry. Germany, the United Kingdom, France, Italy, and Spain continue contributing significantly to therapeutic development.

Asia Pacific is expected to experience the fastest growth during the forecast period due to increasing mental health awareness, expanding healthcare infrastructure, rising research investment, and growing participation in international clinical trials across China, Japan, South Korea, India, and Australia.

Latin America and the Middle East & Africa are gradually strengthening mental healthcare systems through improved access to psychiatric services, expanding clinical research capabilities, and increasing government support for mental health initiatives.

Competitive and Strategic Outlook

The global schizophrenia emerging therapies market is highly competitive, with multinational pharmaceutical companies, biotechnology firms, academic institutions, and neuroscience-focused developers actively pursuing innovative therapeutic solutions. Competition increasingly centers on therapies capable of improving efficacy, reducing adverse effects, enhancing cognitive outcomes, and addressing negative symptoms that remain inadequately treated by existing medications.

Organizations continue investing in artificial intelligence-assisted drug discovery, biomarker research, precision psychiatry, digital therapeutics, long-acting formulations, and novel molecular targets. Strategic collaborations, licensing agreements, mergers and acquisitions, co-development partnerships, and venture capital investments continue accelerating innovation while strengthening competitive positioning.

Future competition is expected to emphasize personalized treatment strategies, combination therapies, digital health integration, biomarker-guided prescribing, and next-generation antipsychotic agents capable of improving long-term functional recovery and quality of life.

Conclusion

The global schizophrenia emerging therapies market is expected to experience sustained growth as advances in neuroscience, precision medicine, digital health, and psychiatric drug discovery continue transform the treatment landscape. Increasing research investment, expanding therapeutic pipelines, supportive regulatory initiatives, and growing understanding of schizophrenia biology are expected to drive continued innovation throughout the forecast period. Although challenges related to complex disease mechanisms, clinical development risks, and reimbursement remain, ongoing scientific progress is expected to accelerate the availability of more effective, safer, and personalized therapies for individuals living with schizophrenia.

Key Benefits of this Report

• Insightful Analysis: Comprehensive evaluation of emerging therapies, clinical pipelines, innovation trends, and market opportunities.
• Competitive Landscape: Understand strategic initiatives, pipeline positioning, licensing activities, and competitive developments.
• Market Drivers and Future Trends: Assess technological advancements, therapeutic innovations, and future commercialization prospects.
• Actionable Recommendations: Support investment decisions, product development, market entry, and portfolio planning.
• Caters to a Wide Audience: Suitable for pharmaceutical companies, biotechnology firms, investors, healthcare providers, consultants, research institutions, and policymakers.

What Businesses Use Our Reports For

Pipeline assessment, emerging therapy evaluation, investment planning, competitive intelligence, clinical development strategy, licensing analysis, market entry planning, portfolio optimization, and commercialization strategy.

Report Coverage

• Historical analysis from 2021 to 2024, Base year 2025, and Forecast period from 2026 to 2035
• Emerging therapy pipeline analysis by development stage, mechanism of action, therapy type, route of administration, and region
• Clinical development trends, regulatory landscape, licensing activities, and innovation outlook
• Competitive landscape, strategic partnerships, investment trends, and commercialization opportunities
• Regional market analysis across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
• 1.2 Emerging Therapy Landscape Overview
• 1.3 Key Pipeline Intelligence Highlights
• 1.4 Emerging Mechanism Trends
• 1.5 Clinical Development Snapshot
• 1.6 Probability-Adjusted Opportunity Assessment
• 1.7 Competitive Intelligence Highlights
• 1.8 Strategic Implications for Stakeholders

2. Pipeline Overview

• 2.1 Schizophrenia Emerging Therapy Market Overview
  • 2.1.1 Evolution of Schizophrenia Drug Development
  • 2.1.2 Current Treatment Paradigm and Innovation Gaps
  • 2.1.3 Historical Therapeutic Advancements
  • 2.1.4 Emerging Therapy Development Trends
• 2.2 Pipeline Landscape Summary
  • 2.2.1 Total Active Emerging Therapy Assets
  • 2.2.2 Total Active Sponsors and Developers
  • 2.2.3 Pipeline Distribution by Development Phase
  • 2.2.4 Pipeline Distribution by Mechanism of Action
  • 2.2.5 Pipeline Distribution by Therapeutic Modality
  • 2.2.6 Pipeline Distribution by Geography
• 2.3 Historical Pipeline Evolution
  • 2.3.1 Five-Year Asset Growth Trends
  • 2.3.2 Clinical Advancement Trends
  • 2.3.3 Historical Attrition Analysis
  • 2.3.4 Approval and Regulatory Milestone Trends

3. Disease and Unmet Need Analysis

• 3.1 Disease Burden Assessment
  • 3.1.1 Epidemiology Overview
  • 3.1.2 Healthcare Burden
  • 3.1.3 Socioeconomic Impact
  • 3.1.4 Quality-of-Life Burden
• 3.2 Current Treatment Limitations
  • 3.2.1 Persistent Positive Symptoms
  • 3.2.2 Negative Symptoms Burden
  • 3.2.3 Cognitive Dysfunction
  • 3.2.4 Treatment Resistance
  • 3.2.5 Relapse and Recurrence
  • 3.2.6 Medication Adherence Challenges
  • 3.2.7 Long-Term Safety Concerns
• 3.3 Future Therapeutic Needs
  • 3.3.1 Novel Target Development
  • 3.3.2 Precision Psychiatry Opportunities
  • 3.3.3 Functional Recovery-Oriented Treatments
  • 3.3.4 Biomarker-Based Development Approaches
  • 3.3.5 Digital and Hybrid Therapeutic Integration

4. Mechanism and Modality Landscape

• 4.1 Mechanism of Action Landscape
  • 4.1.1 Dopamine Receptor Modulation
  • 4.1.2 Dopamine D2/D3 Partial Agonists
  • 4.1.3 Serotonin-Dopamine Modulators
  • 4.1.4 Muscarinic Receptor Agonists
  • 4.1.5 TAAR1 Agonists
  • 4.1.6 Glutamate Receptor Modulators
  • 4.1.7 GABAergic Pathway Modulators
  • 4.1.8 Neuroinflammatory Targets
  • 4.1.9 Multi-Mechanism Therapeutics
  • 4.1.10 Emerging Novel Targets
• 4.2 Innovation Assessment
  • 4.2.1 First-in-Class Candidates
  • 4.2.2 Best-in-Class Candidates
  • 4.2.3 Disruptive Innovation Programs
  • 4.2.4 High-Risk High-Reward Assets
• 4.3 Modality Landscape
  • 4.3.1 Small Molecule Therapeutics
  • 4.3.2 Biologic Therapeutics
  • 4.3.3 RNA-Based Therapeutics
  • 4.3.4 Cell and Gene Therapy Programs
  • 4.3.5 Combination Therapies
  • 4.3.6 Digital Therapeutic Integration
• 4.4 Competitive Mechanism Clustering
  • 4.4.1 Asset Density by MoA
  • 4.4.2 Innovation White Space Assessment
  • 4.4.3 Sponsor Concentration Analysis

5. Clinical Development Intelligence

• 5.1 Clinical Trial Landscape
  • 5.1.1 Active Clinical Trial Inventory
  • 5.1.2 Trial Growth Trends
  • 5.1.3 Sponsor Activity Analysis
  • 5.1.4 Trial Distribution by Phase
• 5.2 Trial Design Benchmarking
  • 5.2.1 Sample Size Analysis
  • 5.2.2 Primary Endpoint Benchmarking
  • 5.2.3 Secondary Endpoint Analysis
  • 5.2.4 Trial Duration Trends
  • 5.2.5 Comparator Selection Trends
  • 5.2.6 Inclusion and Exclusion Criteria Assessment
• 5.3 Clinical Development Performance
  • 5.3.1 Recruitment Timelines
  • 5.3.2 Enrollment Efficiency
  • 5.3.3 Retention and Dropout Trends
  • 5.3.4 Protocol Amendment Analysis
  • 5.3.5 Trial Completion Rates
• 5.4 Success and Failure Intelligence
  • 5.4.1 Historical Success Rates by Phase
  • 5.4.2 Historical Failure Rates by Phase
  • 5.4.3 Scientific Failure Drivers
  • 5.4.4 Clinical Failure Drivers
  • 5.4.5 Regulatory Risk Factors

6. Pipeline Segmentation

• 6.1 Pipeline by Development Phase
  • 6.1.1 Preclinical Assets
  • 6.1.2 Phase I Assets
  • 6.1.3 Phase II Assets
  • 6.1.4 Phase III Assets
  • 6.1.5 Filed / Under Regulatory Review Assets
• 6.2 Pipeline by Mechanism of Action
• 6.3 Pipeline by Therapeutic Modality
• 6.4 Pipeline by Target Patient Population
• 6.5 Pipeline by Sponsor Type
• 6.6 Asset-Level Emerging Therapy Profiles
  • 6.6.1 Standard Asset Evaluation Framework

7. Probability of Success and Risk Analysis

• 7.1 Phase Transition Probability Modeling
  • 7.1.1 Preclinical to Phase I
  • 7.1.2 Phase I to Phase II
  • 7.1.3 Phase II to Phase III
  • 7.1.4 Phase III to Regulatory Approval
  • 7.1.5 Overall Likelihood of Approval
• 7.2 Risk-Adjusted Pipeline Valuation
  • 7.2.1 Risk-Weighted Asset Ranking
  • 7.2.2 Probability-Adjusted Portfolio Assessment
  • 7.2.3 Sponsor-Level Risk Assessment
• 7.3 Attrition Analysis
  • 7.3.1 Scientific Attrition Risk
  • 7.3.2 Clinical Attrition Risk
  • 7.3.3 Regulatory Attrition Risk
  • 7.3.4 Commercial Attrition Risk
• 7.4 Scenario Analysis
  • 7.4.1 Base Case Scenario
  • 7.4.2 Optimistic Scenario
  • 7.4.3 Conservative Scenario

8. Launch Timeline and Commercial Potential

• 8.1 Expected Regulatory Milestones
  • 8.1.1 Near-Term Approval Candidates
  • 8.1.2 Mid-Term Approval Candidates
  • 8.1.3 Long-Term Approval Candidates
• 8.2 Launch Sequencing Analysis
• 8.3 Competitive Entry Timing
• 8.4 Market Access Assessment
• 8.5 Peak Sales Potential Analysis
• 8.6 Probability-Weighted Revenue Forecasts
• 8.7 Commercial Risk Evaluation

9. Competitive Pipeline Landscape

• 9.1 Company-Wise Pipeline Strength Analysis
• 9.2 Emerging Therapy Leaderboard
• 9.3 Pipeline Concentration Assessment
• 9.4 Leader vs Challenger Positioning
• 9.5 Innovation Leadership Matrix
• 9.6 Emerging Biotechnology Companies
• 9.7 Academic and Research Institution Participation
• 9.8 Competitive Outlook

10. Geographic Analysis

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 Latin America
• 10.5 Middle East & Africa

11. Key Countries Analysis

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 China
• 11.9 Japan
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia
• 11.16 South Africa

12. Deals and Investment Landscape

• 12.1 Licensing Activity
• 12.2 Co-Development Partnerships
• 12.3 Mergers and Acquisitions
• 12.4 Funding Landscape
• 12.5 Investment Trend Analysis

13. Future Outlook and Strategic Insights

• 13.1 Future Scientific Directions
• 13.2 Emerging Mechanism Opportunities
• 13.3 Next-Generation Therapeutic Platforms
• 13.4 Future Competitive Dynamics
• 13.5 High-Potential Development Areas
• 13.6 Strategic Recommendations for Developers
• 13.7 Strategic Recommendations for Investors
• 13.8 Strategic Recommendations for Licensing Partners
• 13.9 Long-Term Emerging Therapy Outlook (2025-2040)

14. Methodology and Data Framework

• 14.1 Research Methodology
• 14.2 Data Collection Framework
• 14.3 Source Validation Framework
• 14.4 Asset Inclusion Criteria
• 14.5 Phase Classification Methodology
• 14.6 Mechanism Classification Methodology
• 14.7 Probability of Success Modeling Framework
• 14.8 Risk Adjustment Methodology
• 14.9 Commercial Forecasting Methodology
• 14.10 Competitive Benchmarking Framework
• 14.11 Limitations and Assumptions
• 14.12 Data Verification Process